What is B. Riley's Forecast for SNDX Q3 Earnings?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Research analysts at B. Riley issued their Q3 2025 earnings per share estimates for Syndax Pharmaceuticals in a report released on Monday, March 3rd. B. Riley analyst K. Patel anticipates that the company will post earnings of ($1.12) per share for the quarter. The consensus estimate for Syndax Pharmaceuticals' current full-year earnings is ($3.72) per share. B. Riley also issued estimates for Syndax Pharmaceuticals' Q4 2025 earnings at ($1.06) EPS, FY2025 earnings at ($4.40) EPS, FY2026 earnings at ($3.56) EPS and FY2027 earnings at ($2.29) EPS.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Monday, March 3rd. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The business had revenue of $7.68 million for the quarter, compared to the consensus estimate of $86.32 million.

A number of other equities research analysts have also recently weighed in on SNDX. Citigroup dropped their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. JPMorgan Chase & Co. boosted their price target on shares of Syndax Pharmaceuticals from $35.00 to $39.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 4th. StockNews.com cut shares of Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, November 23rd. HC Wainwright restated a "buy" rating and issued a $51.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. Finally, Scotiabank reduced their target price on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating on the stock in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $36.00.

Remove Ads

Syndax Pharmaceuticals Price Performance

Shares of NASDAQ:SNDX traded down $0.89 during mid-day trading on Thursday, reaching $12.53. 1,873,839 shares of the company were exchanged, compared to its average volume of 2,344,236. The firm has a market cap of $1.08 billion, a price-to-earnings ratio of -3.45 and a beta of 0.92. Syndax Pharmaceuticals has a 1 year low of $12.06 and a 1 year high of $25.07. The firm's 50-day simple moving average is $14.33 and its 200 day simple moving average is $16.58.

Insider Transactions at Syndax Pharmaceuticals

In other news, CFO Keith A. Goldan sold 3,777 shares of the business's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $58,543.50. Following the completion of the sale, the chief financial officer now owns 90,746 shares in the company, valued at approximately $1,406,563. The trade was a 4.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Neil Gallagher sold 4,618 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $71,579.00. Following the completion of the transaction, the insider now directly owns 85,095 shares in the company, valued at $1,318,972.50. This trade represents a 5.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 21,683 shares of company stock valued at $336,087. 4.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company's stock valued at $58,000 after purchasing an additional 541 shares during the period. Atria Investments Inc purchased a new stake in Syndax Pharmaceuticals during the 3rd quarter valued at approximately $364,000. Simplify Asset Management Inc. lifted its position in Syndax Pharmaceuticals by 62.5% during the 3rd quarter. Simplify Asset Management Inc. now owns 122,185 shares of the company's stock worth $2,352,000 after acquiring an additional 46,992 shares during the period. Quest Partners LLC grew its stake in shares of Syndax Pharmaceuticals by 31.0% in the 3rd quarter. Quest Partners LLC now owns 17,858 shares of the company's stock valued at $344,000 after purchasing an additional 4,223 shares during the last quarter. Finally, First Turn Management LLC increased its holdings in shares of Syndax Pharmaceuticals by 85.4% in the third quarter. First Turn Management LLC now owns 1,187,165 shares of the company's stock valued at $22,853,000 after purchasing an additional 546,776 shares during the period.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).